Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a tiny sensor replace the glucose drink test for new moms?

NCT ID NCT06184373

Knowledge-focused Sponsor: Ohio State University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a continuous glucose monitor (CGM) — a small sensor worn under the skin — is an acceptable and useful tool for checking diabetes risk in women who recently had gestational diabetes. Twenty women will wear the CGM for 10 days at 6-8 weeks after giving birth, then complete surveys about their experience. The goal is to see if CGM could improve low follow-up rates for postpartum diabetes screening.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
continuous glucose monitor (CGM)
What this could lead to
If successful, this could show that CGM is a practical and acceptable way to screen for diabetes risk after gestational diabetes, potentially improving follow-up care.
What could go wrong
This is a very small early study (20 participants) focused on acceptability, not on proving that CGM prevents diabetes. Results may not apply to all women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

We anticipate enrolling a total of 20 participants with a recent pregnancy affected by GDM

Ages

18 to 50 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women with a viable singleton intrauterine pregnancy * Able to understand the study, and having understood, provide written informed consent in English * Recent pregnancy affected by gestational diabetes Exclusion Criteria: * Pregestational Diabetes (Type I or Type II) * Continued use of diabetes medications (including metformin and insulin) immediately after delivery * Preterm delivery (\< 37 weeks gestation) * Twin or higher order gestation * No access to a smartphone * Unable or unwilling to wear CGM or return for follow up at postpartum mother-infant dyad clinic * Participation in this trial in a prior pregnancy * History of skin allergy to adhesive products or CGM

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gestational diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gestational diabetes hyperglycemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gestational diabetes Hyperglycemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ohio State University Medical Center

    RECRUITING

    Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.